Skip to main content
Home / News / Certara’s Simcyp™ Co-Founders receive the 2022 Innovation Award by International Society of Pharmacometrics

Certara’s Simcyp™ Co-Founders receive the 2022 Innovation Award by International Society of Pharmacometrics

ISoP recognizes innovative science and outstanding leadership in the field of Pharmacometrics and related scientific areas

PRINCETON, NJ.— November 2, 2022 – Certara, Inc., the global leader in biosimulation, today announced that Amin Rostami, Ph.D and Geoff Tucker, Ph.D., co-founders of Simcyp (now, a division of Certara), have received the 2022 Innovation Award by the International Society of Pharmacometrics (ISoP) for their innovative contributions that have advanced/revolutionized the field of pharmacometrics and related scientific areas.

Dr.  Rostami, Senior Vice President of Research & Development and Chief Scientific Officer at Certara, leads the latest scientific advances in the field of biosimulation in every stage of drug development. He is world renowned for his contribution to mechanistic modeling (e.g. physiologically-based pharmacokinetics; PBPK) and has been an invited speaker at over 200 international meetings, in addition to leading numerous workshops in the area of IVIVE-PBPK linked models.

Dr. Tucker, now retired, co-founded Simcyp with Dr. Rostami in 2001 as a spinoff from the University of Sheffield, UK.  He is an expert in the ongoing advancement of pharmacokinetics, drug metabolism, pharmacogenetics, and the pharmacology of anesthetic drugs.

The ISoP Innovation Award recognizes an outstanding scientist or an exceptional team of scientists for their novel, innovative, creative, and remarkable scientific, technical, and methodological contributions to and the advancement of the scientific field of Pharmacometrics.

Congratulations again to Dr. Rostami and Dr. Tucker for winning this award in recognition of their outstanding contributions to the field of quantitative pharmacology. Learn more about Simcyp at

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.

About ISoP

The purpose of the International Society of Pharmacometrics (ISOP) is to promote and advance the discipline of Pharmacometrics and broaden its impact. We are individuals from around the globe from various backgrounds in pharmaceutics, engineering, statistics, and mathematics, who are passionate about advancing and promoting the field of Pharmacometrics.